Right ventricular (RV) diastolic-stiffness is increased in pulmonary arterial hypertension (PAH) patients. We investigated whether RV diastolic-stiffness is associated with clinical progression and assessed the contribution of RV wall-thickness to RV systolic and diastolic-stiffness.
INTRODUCTION
In pulmonary arterial hypertension (PAH) pulmonary vascular remodeling leads to a typical fourfold increase in pulmonary artery pressure. The right ventricle (RV) copes with this increased pressure by converting from a low-to high-pressure pump. As long as this adaptation process is successful, cardiac output and oxygen supply to all organs are assured. Important mechanisms to adapt to an increase in pressure include increased muscle mass and enhanced intrinsic myocyte contractility. Both adaptations have been described in PAH-patients and explain the observed increase in RV systolic elastance (Ees, a measure of ventricular contractile function) in PAH-patients. [1] [2] [3] [4] [5] [6] However, potential consequences of RV systolic adaptation are increased myocardial stiffness and impaired relaxation. Indeed, we recently showed impaired RV diastolic function in PAH-patients. 1 Hypertrophy, fibrosis and stiffening of the RV cardiomyocytes all appeared to contribute to the observed RV diastolic stiffness. 1 However, this analysis was performed in end-stage PAH-patients.
Therefore, it remains unclear whether RV diastolic impairment already plays a role at earlier stages of the disease, and whether it is associated with clinical progression. Because RV hypertrophy is already present at early stages of the disease, it could be hypothesized that the initial increase in RV diastolic stiffness is explained by the increase in wall thickness. This in contrast with end-stage PAH, in which further increases in diastolic stiffness may relate to intrinsic sarcomere stiffening. Therefore, the aims of this study are: 1. To investigate whether increased RV diastolic stiffness is associated with clinical progression in baseline and treated PAH-patients; 2. To assess the contribution of RV wall thickness to RV diastolic stiffness in different disease stages, and 3. To describe the change in RV diastolic stiffness during follow-up.
METHODS

Subjects: control, baseline and treated cases
All patients diagnosed with idiopathic and heritable PAH at the VU University Medical Center from August 10 1989 until 25 February 2014 were evaluated for inclusion in the current study. 7 Part of the patient selection procedure has been described before. 6 Baseline patients: For the assessment of the relation between diastolic stiffness and clinical progression and RV systolic adaptation, baseline treatment-naïve patients with digitally stored good Chapter 5 quality RV pressure recordings and a cardiac MRI performed within four weeks from right heart catheterization were included (FIGURE 5.1, n=63). Reasons for excluding patients were: no stored RV pressure curves at the time of diagnosis (n=48) and RV pressure curves that were of poor quality (n=15). 
Treated patients:
The association between a high diastolic stiffness and clinical progression was further assessed in treated patients. In addition, these patients were used to determine a) the relation between RV diastolic stiffness and RV systolic adaptation and b) the interaction between RV wall thickness and RV systolic and diastolic function (FIGURE 5.1). We retrospectively determined the availability of good quality RV pressure curves recorded during follow-up and within four weeks from a cardiac MRI in all idiopathic and heritable PAH patients seen in our hospital. We included patients with these measurements based on their survival time after their follow-up measurement. Patients who were alive and who had a follow-up time <5 years after the measurement were not included. The remaining patients either survived >5 years or died or underwent lung transplantation. These patients were divided into two groups, i.e. survival <5 and >5 years after the follow-up measurements (PAHsurvival<5yrs and PAHsurvival>5yrs). Of the latter group, only 2 out of 22 included patients had an event during follow-up.
Treatment response: For the assessment of the change in diastolic stiffness under treatment, we performed a follow-up analysis in a subgroup (n=30) of the baseline patient population in whom RV pressure curves and cardiac MRI were available 0.5-2.5 years after the baseline measurement.
All PAH patients
Baseline patients n=63
Treated patients n=45
Survival <5 years n=23
Survival >5 years n=22
Assessment of:
• 
Right heart catheterization
Right heart catheterization was performed as previously described. 6 A detailed description can be found in the online data supplement. Mean PAP was averaged over at least two respiratory cycles.
Cardiac output (CO) was measured by either the direct Fick method or thermodilution. Stroke volume (SV) was calculated as CO divided by heart rate. CO and SV were indexed for body surface area (BSA).
Total pulmonary vascular resistance (TPVR) was calculated as mPAP and divided by CO (Woods units, mmHg/min/L).
Cardiac magnetic resonance imaging
All MR images were acquired with a 1.5 Tesla Avanto or Sonata MRI system equipped with a 6-element phased array coil (Siemens Medical Solutions, Erlangen, Germany) as previously described. 6 A stack of short-axis images was taken at breath-hold per slice, with a slice thickness and interslice gap of 5mm.
RV volumes and mass were determined by manually drawing endocardial and epicardial borders at end-diastole and end-systole using Mass Analysis software (MEDIS Medical Imaging Systems, Leiden,
The Netherlands). End-diastole was defined as the onset of the R-wave of the ECG. End-systole was determined visually as the smallest volume during the cardiac cycle. Relative wall thickness was calculated by dividing RV mass by RV end-diastolic volume. RV ejection fraction (RVEF) = (RVEDV-RVESV)/RVEDV*100%, where RVEDV is RV end-diastolic volume and RVESV is RV end-systolic volume.
Data analysis
Pressure-volume analysis
Part of the data analysis has been previously described. 1, 6, 8 A detailed description of the data analysis can be found in the online data supplement. The slope of the end-systolic pressure-volume relation (Ees, a measure of RV systolic function) was calculated as follows: Ees = (Piso-mPAP)/(EDV-ESV). RV isovolumic pressure (Piso) per beat was determined according to the single-beat method of Sunagawa. 9,10 Arterial elastance (Ea, a measure of afterload) was calculated by dividing mPAP by SV.
RV-arterial coupling (RV systolic adaptation to arterial load) was then calculated as the ratio between
Ees and Ea. Diastolic stiffness was assessed by end-diastolic elastance (Eed). The diastolic pressure-
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volume relation was determined as described previously, see online data supplement. 1 In previous studies 1 , we used β (the diastolic stiffness constant) of the exponential pressure-volume relation described by the formula: P=α (e Vβ -1), see FIGURE 5.2A. Since β describes only part of the enddiastolic pressure-volume relation, we used Eed in the present study. Eed was calculated as the slope of the diastolic pressure-volume relation at end-diastole using both α and β in the following formula: 
Statistical analysis
The data are presented as means ± SEM unless stated otherwise. A p-value < 0.05 was considered 
RESULTS
Relation between RV diastolic stiffness and clinical progression
To investigate whether RV diastolic stiffness is related to clinical progression, we first compared clinical characteristics of baseline patients with a low and high RV diastolic stiffness (median-based cut-off value 0.53 mmHg/ml). TABLE 5.1 shows that patients with a high diastolic stiffness had a higher mPAP, TPVR and mean right atrial pressure (mRAP) when compared to patients with a low diastolic stiffness. RV volumes were similar in the two groups, while patients with a high diastolic stiffness exhibited a lower RV ejection fraction and a higher RV mass and relative wall thickness. Interestingly, pressure-volume analysis revealed that despite of the higher afterload seen in patients with a higher diastolic stiffness, RV-arterial coupling was similar. A survival analysis based on baseline values of RV diastolic stiffness showed that age-corrected survival was worse for patients with a high diastolic stiffness (FIGURE 5.3 ). Similar findings were observed when using an ROC analysis-based optimal Eed cut-off value as presented in the online supplement (SUPPLEMENTAL FIGURE 5.1S). Univariate cox-regression analysis on RV function indices using continuous variables revealed that 
.4). However, in
PAHsurvival<5yrs but not in PAHsurvival>5yrs, the reduced RV-arterial coupling coincided with increased RV diastolic stiffness. Together, these data together suggest that RV diastolic stiffening is closely associated with clinical progression in both baseline as well as treated PAH-patients. 
RV relative wall thickness and diastolic stiffness in different disease stages
To investigate whether the increased Ees and Eed in PAHsurvival>5yrs and PAHsurvival<5yrs are a sole consequence of increased RV wall thickness, we subsequently calculated wall thickness corrected Ees and Eed values. As can be observed in FIGURE 5.5, Ees values remained increased after correction for RV wall thickness. In contrast, wall thickness-corrected Eed values were normal in PAHsurvival>5yrs, whereas in PAHsurvival<5yrs wall thickness-corrected Eed values was significantly increased. These data suggest that diastolic stiffness in stable patients may be largely explained by hypertrophy, while in progressive patients additional intrinsic factors may play a role in increasing diastolic stiffness. 
Relation between RV diastolic stiffness and systolic adaptation
To assess whether diastolic stiffness is associated with impaired RV systolic adaptation, we 
DISCUSSION
In the present study we assessed RV diastolic stiffness in a large cohort of baseline and treated PAHpatients and demonstrated that: 1) diastolic stiffening is associated with clinical progression in both baseline as well as treated PAH-patients, 2) diastolic stiffness in treated PAH-patients with a survival >5 years is largely explained by increased RV wall thickness, whereas in PAH-patients RV with a survival <5 years diastolic stiffness remains increased after correction for RV wall thickness, 3) RV diastolic stiffness is only weakly associated with impaired RV systolic adaptation in treated PAH-patients, while no relation exists in baseline PAH-patients, 4) RV diastolic stiffness decreases >10% during follow-up in the majority of PAH-patients, but overall no statistical significant decrease in diastolic stiffness can be observed.
The clinical importance of RV diastolic stiffness
Previous large PAH-patient cohort studies have demonstrated the clinical importance of loaddependent measures of RV diastolic stiffening such as RA pressure, increased atrium-dependent RV filling, and prolonged RV isovolumic relaxation. [11] [12] [13] [14] [15] Especially RA pressure is one of the parameters that is frequently identified as predictor of survival in multivariate survival analyses. 11 We have recently introduced a novel method to assess RV diastolic stiffness in a load-independent fashion using a single-beat, diastolic pressure-volume analysis. 1 Load-independent assessment of RV diastolic stiffness is scientifically important, as it provides insight in the intrinsic alterations of the RV myocardium independently from the degree of pressure overload. Recently, VanderPool showed that RV diastolic stiffness relates to survival 16 , but this association was not observed when a correction was made for RAP, mean PAP and stroke volume. As this analysis was performed in a mixed group of WHO group I (including connective-tissue disease associated PAH) and WHO group II PH patients, it remains unknown whether load-independent RV diastolic stiffness is related to clinical progression and development of right heart failure in idiopathic PAH patients. Therefore, we investigated the association between clinical progression and RV diastolic stiffness and observed an association in both treated as well as baseline PAH-patients.
Subsequently, we were interested in the relation between RV diastolic stiffness and RV systolic adaptation. Both systolic and diastolic function are closely modulated on a cellular level by calcium flux and sarcomeric function, and on ventricular level by wall mass. 13, 17 Recently, we identified in
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tissue samples from end-stage PAH-patients, changes in protein expression of important calcium handling proteins indicating prolonged diastolic calcium clearance. 18 Furthermore, increased calcium sensitivity of the sarcomeric proteins may add to RV systolic adaptation as less calcium would be needed to obtain a similar force development. 1, 18 However, at the same time increased calcium sensitivity will affect relaxation of the RV cardiomyocytes, thereby inducing diastolic stiffening of the RV. Therefore, we recently proposed that in early stages of PAH, RV diastolic stiffness may result from the adaptation mechanisms that are induced to preserve RV systolic adaptation as long as possible, such as ventricular wall mass and increased calcium sensitivity. 19 In later stages, RV diastolic stiffness will become more prevalent due to stiffening of the RV cardiomyocytes itself, which will eventually hamper RV systolic adaptation in end-stage PAH. 15, 19, 20 In this study, support for this hypothesis was provided by finding increased RV diastolic stiffness in baseline PAH-patients in whom RV systolic adaptation was relatively preserved. Moreover, only in treated PAH-patients, RV diastolic stiffness coincided with impaired RV systolic adaptation.
Possible mechanisms of RV diastolic stiffness in PAH
To obtain more insight into the mechanism of RV diastolic stiffness and systolic function in different stages of PAH, we calculated systolic elastance corrected for relative wall thickness. We used relative wall thickness (EDV/RV mass) as to control for both the effect volume and hypertrophy has on systolic and diastolic stiffness. After correction for wall thickness, RV systolic function was increased in all PAHpatients in comparison to controls. This indicates that in addition to the increased RV wall mass, intrinsic alterations in the cardiac muscle are important in determining increased systolic function of the RV in PAH. RV diastolic stiffness corrected for wall-thickness was not different from control subjects in PAH-patients with a survival >5 years. This may indicate that RV diastolic stiffness in early or stable PAH is a mere consequence of RV systolic adaptation. In PAH-patients with a survival <5 years, RV diastolic stiffness is increased out of proportion to the increase in wall thickness, which indicates that intrinsic cardiac muscle alterations play an additional role in determining diastolic stiffness in more advanced PAH. One such intrinsic alteration could be RV cardiomyocyte stiffening due to hypo-phosphorylation of the giant sarcomeric protein titin, which we recently showed in RV samples of end-stage PAH-patients. 18 Another possible mechanism of RV diastolic stiffness may be increased collagen deposition, although until now only modest increases in RV fibrosis have been reported in clinical PAH. 1
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Clinical implications
With the present study we show that in a large baseline and treated PAH patient cohort RV diastolic stiffness is associated with clinical progression. RV diastolic stiffness decreases >10% in the majority of patients, but showed no statistical significant decrease in the total group analysis. The minimal decrease in RV diastolic stiffness coincided with a decrease in relative wall thickness, indicating that treatment has little or no effect on intrinsic RV diastolic stiffness. These findings should be subject for further evaluation and underscores the need to further explore the additive value of the determination of diastolic stiffness in predicting patient outcome. Moreover, future studies are needed to provide tools to noninvasively assess RV diastolic function. Currently, the available noninvasive techniques (echocardiography and MRI measured relaxation velocities and filling patterns) have significant drawbacks (load-dependency) which limits the clinical applicability of noninvasive load-independent RV diastolic evaluation. [21] [22] [23] However, studies on the assessment of diastolic wall strain in patients with left ventricular diastolic dysfunction have shown promising results, making diastolic wall strain a possible future evaluation tool for RV diastolic dysfunction in PAH. [24] [25] 
Conclusions
With the present study we demonstrate that RV diastolic stiffening is associated to clinical progression in both baseline as well as treated PAH-patients. We additionally show that RV diastolic stiffness in treated PAH-patients with a survival >5 years is largely explained by increased RV wall thickness, whereas in PAH-patients with a survival <5 years the further increase in RV diastolic stiffness is most likely related to additional intrinsic alterations of the myocardium. Furthermore, RV diastolic stiffness is only weakly associated with impaired RV systolic adaptation in treated PAH-patients, while no relation exists in baseline PAH-patients.
SUPPLEMENTAL DATA
METHODS
Right heart catheterization and cardiac MRI
Right heart catheterization was performed as previously described. 1, 2 . Under local anesthesia and constant ECG monitoring, a balloon-tipped Swan-Ganz catheter (Edwards Lifesciences, LLC, Irvine, CA) was inserted via the jugular vein and pulmonary artery, right ventricular and right atrial pressures were measured. A Powerlab data acquisition system (AD Instruments, Sydney, Australia) was used to register pressure curves alongside the standard pressure recordings. To obtain high quality pressure curves without artifacts we used shielded pressure transducers with a resistance serially connected to increase damping and flushed the catheter repeatedly with heparin to avoid potential underdamping due to blood clots. Mean PAP was averaged over at least two respiratory cycles.
Cardiac output (CO) was measured by either the direct Fick method or thermodilution. Stroke volume (SV) was calculated as CO divided by heart rate. Cardiac output and SV were indexed for body surface area (BSA). Total pulmonary vascular resistance was calculated as mPAP divided by CO (Woods units, mmHg/min/L).
Data analysis
Ees, Ea and RV-arterial coupling
Part of the data analysis has been previously described. 1 The slope of the ESPVR (Ees) was calculated as follows: Ees = (Piso-mPAP)/(EDV-ESV). In this calculation mPAP is mean pulmonary artery pressure and taken as a surrogate of RV end-systolic pressure. 3,4,5 RV isovolumic pressure (Piso) per beat was determined according the single-beat method of Sunagawa. 6, 7, 8 With this method an inverted cosine wave was fitted over the RV pressure curve using the isovolumic contraction period (from end-diastole to the point of maximal rate of pressure rise (dP/dtmax)) and the isovolumic relaxation period (from minimal dP/dt to start diastole) by a semi-automatic Matlab R2008a program (The MathWorks, Natick, MA). The point of end-diastole was identified using the R-wave of the ECG, and when needed manually shifted to the point before the upslope of the ascending limb. To compensate for beat-tobeat variations, the so calculated RV isovolumic pressures were averaged over at least five heartbeats.
End-diastolic volume (EDV) and end-systolic volume (ESV) were determined with cardiac MRI. Arterial elastance (Ea) was calculated by dividing mPAP by EDV-ESV. RV-arterial coupling was then calculated
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as the ratio between Ees and Ea. A non-linear single-beat diastolic pressure-volume relation was determined using the following formula: P=α (e Vβ -1) where P: pressure; α: curve-fitting constant; β: diastolic stiffness constant; V: volume. The three pressure points used to construct the PV relation were recorded at: 1) the minimal pressure decrease of the beginning of the filling phase: begin diastolic pressure (BDP), 2) the maximal pressure rise of the filling phase: end diastolic pressure (EDP) and 3) the 0pressure, point. To avoid measurement errors caused by the positioning of the catheter, BDP was normalized at 1 mm Hg, whereas the EDP was calculated with the following formula:
EDPnormalized=1+EDPinitial-BDPinitial [2] . The three volume points used were as follows: 1) end systolic volume (ESV), 2) end diastolic volume (EDV) and 3) the 0volume point. The exponential pressure-volume relation was constructed using: 1) BDPnormalized-ESV point, 2) EDPnormalized-EDV point and 3) 0pressure-0volume point [2] . Subsequently, end-diastolic elastance (Eed) was determined at end-diastolic volume using α and β in the following formula: α•β•e (β•EDV) .
